Articles tagged with Atrial Fibrillation
Cardiovascular diseases like heart failure and atrial fibrillation are linked to cognitive impairment and increased risk of dementia. Adopting a healthy lifestyle and identifying vascular risk factors early may help preserve brain function and reduce the burden of Alzheimer's disease.
The study finds that chemokines, particularly CXCL12/CXCR4 axis, are upregulated in patients with atrial fibrillation, contributing to increased remodeling and risk of death. Elevated expression of CXCR2 is also linked to monocyte infiltration and accelerated atrial remodeling.
Researchers found that adopting an electronic patient management system for direct oral anticoagulants reduced off-label dosing by 8%, while also decreasing the rate of blood clots and strokes. The online dashboard, used at over 120 hospitals, highlights treatment optimization and improves patient safety.
A new study estimates nearly 10.5 million U.S. adults have A-Fib, a three-fold increase from previous estimates. Early detection and treatment can reduce its adverse outcomes.
A recent study published in JACC: Clinical Electrophysiology found that quitting smoking can significantly lower the risk of atrial fibrillation, with former smokers having around 13% lower risk and current quitters having an 18% lower risk. The benefits of quitting are seen shortly after stopping smoking.
Researchers at the University of Illinois Chicago have identified a cellular pathway essential to obesity-induced atrial fibrillation. Blocking NOX2, an enzyme that produces reactive oxygen species, may prevent and reverse changes in heart structure and function caused by high-fat diets.
A study published in JAMA found that pulmonary vein isolation resulted in a statistically significant decrease in atrial fibrillation burden at 6 months. The procedure also showed substantial improvements in symptoms and quality of life for patients with symptomatic atrial fibrillation.
A recent systematic review and meta-analysis of 28 studies with 1.2 million participants found that wearable technology can accurately detect conditions such as heart rate variability, blood pressure, oxygen levels, sleep quality, skin temperature, hydration, and stress levels. The study suggests that wearable activity trackers could r...
A catheter ablation procedure for atrial fibrillation has been shown to significantly reduce AF burden and improve quality of life compared to a sham procedure. The study found that patients treated with the actual ablation had an average reduction in AF burden of 60% at 6 months, while those receiving the sham procedure saw a smaller ...
A phase III trial found that asundexian was inferior to apixaban in preventing stroke and systemic embolism in high-risk patients with atrial fibrillation. The trial also showed lower bleeding rates with asundexian, but this finding needs to be put into context with the stroke findings.
The EPIC-CAD trial shows that edoxaban monotherapy significantly reduces the risk of primary endpoint, major bleeding, and major ischaemic events compared to dual antithrombotic therapy in patients with high-risk atrial fibrillation and stable coronary artery disease.
Researchers found that supplementing potassium only when levels fell below 3.6 mEq/L was noninferior to the current practice of maintaining higher levels, with no increase in adverse outcomes. Lower thresholds did not worsen clinical outcomes or dysrhythmias.
The new ESC Guidelines focus on tackling atrial fibrillation's growing impact by emphasizing equal care, education, and dynamic re-evaluation. Comorbidities and risk factors are critical to managing AF, with a 'safety-first' approach and shared-decision making on treatment.
A study emulated a clinical trial using real-world UK healthcare data to explore treatment effects in patients with atrial fibrillation. The method found similar outcomes between apixaban and warfarin, but with differences linked to ethnicity and medication use.
Women undergoing cardiac surgery have a lower risk of developing postoperative atrial fibrillation compared to men, but are more vulnerable to its associated long-term morbidities. A study found that once atrial fibrillation develops, women have a significantly higher risk of mortality than men.
A new study found that job strain and effort-reward imbalance at work increase the risk of developing atrial fibrillation, an abnormal heart rhythm. The research suggests that recognizing and addressing psychosocial stressors at work can foster healthy environments.
A study published in Cardiovascular Research Journal found that a gene deficiency in patients with atrial fibrillation leads to reduced energy production in heart cells. PITX2-deficient cardiac cells have smaller and less efficient mitochondria, pushing the heart into an oxygen-deficient stress state.
Researchers analyzed data from 63,700 patients in five clinical trials to understand the impact of clonal hematopoiesis of indeterminate potential (CHIP) on heart disease. They found that patients with CHIP had a 30% higher risk of initial heart attacks but not recurrent events.
A study by Michigan Medicine found that over- or under-dosing anticoagulants can result in serious health conditions, most often occurring after the initial prescription. The researchers evaluated five years of prescribing data and found that nearly 70% of alerts to off-label dosing occurred during a follow-up visit.
Researchers found that a tiny deletion in the titin protein causes developmental defects in embryonic ventricles, leading to increased potassium ion current and abnormal ANP expression. This remodeling leads to impaired atrial contractility and an increased risk of adult atrial fibrillation.
A new study by UNC School of Medicine researchers found that wearable devices can significantly amplify anxiety and increase healthcare use in patients with atrial fibrillation. Patients with Afib who use wearables are more likely to be preoccupied with their heart symptoms and report concerns about their treatment.
A study published in Nature Medicine found that off-the-shelf wearable trackers can monitor the response to two treatments for atrial fibrillation and heart failure. The devices provided clinically useful information similar to in-person hospital assessments, with a neural network helping to analyze missing data.
A randomized, controlled trial found acupuncture to be effective in reducing methadone dose and opioid cravings in patients undergoing methadone maintenance therapy. The study suggests that acupuncture could be a useful adjunctive treatment for individuals receiving MMT, potentially improving their treatment outcomes.
A recent study published in Nature Medicine has shown that pulsed field ablation (PFA) is a safe and effective treatment for patients with atrial fibrillation. The study analyzed over 17,600 patients and found no significant risk of esophageal damage or other complications, increasing confidence in the use of PFA technology.
A large-scale genetic survey found that genes can influence the risk of developing atrial fibrillation. Researchers analyzed over 400,000 individuals and identified six genes whose genetic changes significantly affect a person's risk.
Dr. Harish Manyam has developed a groundbreaking system that addresses potentially dangerous problems associated with traditional pacemakers and defibrillators. The leadless pacemaker, in combination with a novel subcutaneous defibrillator, eliminates the need for lead extraction procedures.
Research from Michigan Medicine found that female patients with atrial fibrillation and tricuspid regurgitation are less likely to receive simultaneous procedures during cardiac surgery, despite guideline recommendations. This disparity may be related to perceived higher risk among women.
Researchers investigate the role of adipokines in atrial fibrillation, revealing their involvement in pathogenesis and associated complications. Obesity is found to play a significant role in inducing systemic changes that contribute to AF development.
Patients with atrial fibrillation who took low doses of direct oral anticoagulants experienced more bleeding episodes during the first three months of treatment. High blood levels of the medications were also associated with an increased risk of bleeding events.
A recent study published in JAMA Cardiology found that dual direct-current cardioversion is significantly more effective than single cardioversion in restoring sinus rhythm in obese patients with atrial fibrillation. The study demonstrated a 98% success rate for dual cardioversion, compared to an 86% success rate for single cardioversion.
Researchers discuss Ibrutinib, a BTK inhibitor approved for chronic lymphocytic leukemia treatment, noting 20-25% of patients experience dose-limiting cardiovascular toxicities. A recent study identifies genetic biomarkers, such as KCNQ1 and GATA4, associated with cardiotoxic events, which may improve risk stratification.
Researchers assessed brain imaging for minor, moderate, and major ischemic strokes to evaluate early direct oral anticoagulant initiation. The study found no difference in treatment effects or adverse event rates among infarct sizes.
Black and Hispanic patients with atrial fibrillation were less likely to initiate direct oral anticoagulants at study onset, but these disparities narrowed over time. The study highlights the need to address unequal access to novel therapies for Black and Hispanic populations.
Researchers found that over 130,000 people in Denmark live with atrial fibrillation, with a 20% increase in new cases each year. The study reveals heart failure is the most common complication, with a risk of death twice as high as stroke after diagnosis.
Researchers developed a deep-learning model to predict atrial fibrillation, giving early warnings with an accuracy of around 80%. The model, called WARN, uses heart rate data to calculate a probability of danger, providing crucial time for preventive measures.
Atrial fibrillation is more common and deadly among young Americans than previously believed, a new study found. The study of over 67,000 patients under 65 years old showed higher rates of hospitalization, stroke, heart attack, comorbidity, and mortality compared to their peers without Afib.
Research published in Heart Rhythm suggests that the three-month blanking period after atrial fibrillation (AF) ablation may not be necessary, as early AF recurrence is a predictor of late recurrence. The authors propose shortening the blanking period to one month, citing studies that show higher risks of long-term recurrence for patie...
A study found that the lifetime risk of atrial fibrillation has increased from 1 in 4 to 1 in 3 over the past two decades. Among those with the condition, 41% are likely to develop heart failure and 21% encounter a stroke. Researchers call for better prevention strategies for heart failure among patients with atrial fibrillation.
A study of 898 patients with atrial fibrillation found that immediate recurrence during the blanking period after radiofrequency catheter ablation correlates with greater costs, hospitalization duration, and elevated 1-year cumulative AF recurrence rate. IEC was identified as an independent predictor of Im-Recurr.
A new study published in the Journal of the American Heart Association suggests that treating gum disease after a heart rhythm ablation procedure can lower oral inflammation and reduce the risk of AFib recurrence. Researchers found that an index measuring the severity of gum inflammation was associated with the return of AFib, highligh...
A clinical trial found that a nasal spray called etripamil effectively and safely treated recurrent episodes of paroxysmal supraventricular tachycardia (PSVT) in patients. The study showed that two-thirds of participants experienced relief within an hour, with an average time needed for symptom relief being 17 minutes.
Atrial fibrillation affects 2% of individuals worldwide and has a significant impact on people's lives. Catheter ablation is an effective treatment option that uses burning or electrical pulses to inactivate abnormal rhythms.
A recent White Paper published in the Canadian Journal of Cardiology analyzes the current understanding of genetics in atrial fibrillation and recommends screening for genetic heart disease in early onset AF cases. This may lead to identification of life-threatening ventricular cardiomyopathy and channelopathy syndromes, highlighting t...
Researchers found that Black individuals carrying genetic variants in the Titin, TTN gene have a high risk of developing atrial fibrillation, heart failure, and dilated cardiomyopathy. The study used data from the All of Us Research Program to examine the role of these genetic mutations in African ancestry individuals.
A large study found that adults who drank two liters or more of sugar- or artificially sweetened drinks per week had a higher risk of irregular heart rhythms. In contrast, drinking one liter or less of pure, unsweetened juice was associated with a lower risk of atrial fibrillation.
A large-scale review published in The Lancet Regional Health Europe provides an update on the recent advances in understanding and managing risk factors for atrial fibrillation (AF). AF affects around 1.4 million people in the UK, causing irregular heart rates and impairing quality of life. Researchers found that a more individualized ...
A new study has found that anabolic steroid use can increase the risk of atrial fibrillation in individuals with existing genetic predisposition to heart diseases. Researchers discovered that testosterone and other male sex hormones used for muscle building can lead to electrical problems in the heart, particularly in young men.
A randomized clinical trial of 1,015 participants found that apixaban did not significantly reduce recurrent stroke risk compared to aspirin in patients with cryptogenic stroke and atrial cardiopathy. The study suggests that alternative treatments may be more effective for preventing stroke recurrence in these patients.
Recent literature review highlights epicardial adipose tissue, chronic inflammation, and autonomic nervous system imbalance as key AF pathogenic factors. Clinical management trends include wearable devices for continuous monitoring and the 4S-AF scheme for comprehensive assessment.
Researchers found rivaroxaban associated with nearly 40 bleeding events per 100 patients over a year, while apixaban had similar bleeding events as warfarin but more major bleeds. Apixaban also showed lower mortality rates compared to the other medications.
Researchers have developed an AI-powered algorithm that can detect the risk of atrial fibrillation (AFib) with high accuracy, even in people with infrequent AFib episodes. This new tool has the potential to reduce the incidence of stroke and heart failure by identifying patients at increased risk and guiding targeted interventions.
A novel prescription wristwatch uses photoplethysmography to detect atrial fibrillation with high accuracy, even in participants with darker skin tones. The Verily Study Watch bridges the gap between long-term monitoring and consumer devices, enabling clinicians to effectively use wearable data for Afib management.
The new guideline emphasizes the importance of disease prevention, risk factor modification, and optimized therapies to manage atrial fibrillation. It also updates guidelines for catheter ablation, anticoagulants, and heart rate management, aiming to improve patient outcomes and reduce stroke risk.
A global study found that apixaban reduced the risk of stroke and blood clotting by 37% in patients with device-detected atrial fibrillation, also known as sub-clinical atrial fibrillation (SCAF). The medication also reduced fatal or disabling stroke by 49%.
A phase 4 clinical trial found that apixaban, an anti-clotting medication, reduced the rate of stroke and blood clots in adults with implanted heart devices experiencing short bouts of asymptomatic, irregular heart rhythms. The study suggests that these individuals may benefit from receiving an anticoagulant.
Researchers found that abelacimab, a Factor XI inhibitor, reduced bleeding compared to rivaroxaban in patients with atrial fibrillation. The study showed significant reduction in hospitalization due to bleeding and almost eliminated gastrointestinal bleeding.
A new anti-clotting medication, abelacimab, has significantly reduced bleeding among people with atrial fibrillation who are at risk of stroke. The AZALEA-TIMI 71 trial found that abelacimab substantially reduced bleeding compared to the current standard of care use of direct-acting oral anticoagulants.
A study published in JAHA found that sleep-related hypoxia is associated with a higher risk of developing atrial fibrillation over time. Regular screening and treatment of sleep apnea may help reduce the likelihood of AFib, especially in those already at high risk.
Earlier onset of atrial fibrillation is associated with an elevated risk of subsequent all-cause dementia, Alzheimer's disease, and vascular dementia. Monitoring cognitive function among patients with atrial fibrillation, especially those younger than 65 years at diagnosis, is crucial.
A new study by UC San Francisco found that poor sleep is significantly associated with a 15% greater risk of experiencing atrial fibrillation the next day. The researchers suggest strategies like going to bed at a reasonable time, avoiding alcohol and caffeine before bedtime, and exercising regularly to improve general sleep quality.